Leonie J.
- Country
- Germany
- Department
- Clinic for Gastroenterology and Hepatology
Research Overview
- Evaluation of Fecal Microbiota Transfer to Overcome Atezolizumab and Bevacizumab Resistance in Advanced Hepatocellular Carcinoma: A Phase II Randomized Controlled Trial
- Phase II Study of Durvalumab and Tremelimumab with Personalized or Standard SIRT in Non-Resectable Hepatocellular Carcinoma
- A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)
Data & Insights
Has run more than one trial at 7 of 61 partner sites.
Specializations
Liver Cancer Therapeutics
This investigator specializes in innovative treatment approaches for hepatocellular carcinoma, with particular emphasis on combining different therapeutic modalities.
- Immunotherapy combinations
- Radioactive microsphere treatments
- Systemic therapy integration
Their research explores advanced treatment strategies for non-resectable liver cancer cases.
Surgical Oncology
The investigator focuses on neoadjuvant therapy approaches in the context of surgically resectable liver cancer, examining innovative pre-surgical treatments.
- Pre-surgical immunotherapy
- Treatment response assessment
- Pathologic response evaluation
Their work aims to improve surgical outcomes through targeted pre-operative interventions.
Microbiome Research
The investigator studies the role of microbiota modulation in cancer treatment, particularly focusing on overcoming resistance to immunotherapy in liver cancer.
- Fecal microbiota transfer
- Immunotherapy resistance
- T cell response analysis
Their research explores novel approaches to enhance immune system responses in cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.